Creatine Kinase Elevation in Patients with Autosomal Dominant Polycystic Kidney Disease on Tolvaptan Treatment

被引：0
|
作者：
Rodriguez-Espinosa, Diana [1 ]
Payan, Elena C. [1 ]
Guillen, Elena [1 ]
Blasco Pelicano, Josep Miquel [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PO1205
引用
收藏
页码：393 / 393
页数：1
相关论文
共 50 条
  • [21] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Rodney D. Gilbert
    Hazel Evans
    Kazeem Olalekan
    Arvind Nagra
    Mushfequr R. Haq
    Mark Griffiths
    Pediatric Nephrology, 2017, 32 : 893 - 896
  • [22] LONG-TERM SAFETY OF TREATMENT WITH TOLVAPTAN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Martins Munoz, Judith
    Espinel, Laura
    De Lorenzo, Alberto
    Tarragon, Blanca
    Teresa Naya, Maria
    Cubas, Alfonso
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I15 - I15
  • [23] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Gilbert, Rodney D.
    Evans, Hazel
    Olalekan, Kazeem
    Nagra, Arvind
    Haq, Mushfequr R.
    Griffiths, Mark
    PEDIATRIC NEPHROLOGY, 2017, 32 (05) : 893 - 896
  • [24] Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis
    Xie, Xuan
    Cai, Qian
    Guo, Xiao-Yuan
    Bai, Dong-Hai
    Sheng, Hai-Zhong
    Wang, Bao-Kui
    Yan, Kai
    Lu, An-Ming
    Wang, Xin-Ran
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2020, 23 (01) : 6 - 16
  • [25] Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Shimoda, Naoko
    Ikeda, Mariko
    Yan, Tomohiro
    Kawasaki, Sayuri
    Hirama, Akio
    Kashiwagi, Tetsuya
    Sakai, Yukinao
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2022, 89 (03) : 287 - 294
  • [26] In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”
    Shigeo Horie
    Satoru Muto
    Clinical and Experimental Nephrology, 2016, 20 : 149 - 150
  • [27] In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease"
    Horie, Shigeo
    Muto, Satoru
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 149 - 150
  • [28] EFFECT OF TOLVAPTAN ON A BODYWATER BALANCE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Makita, Minoru
    Nishio, Saori
    Kondo, Keiichi
    Kawashima, Keisuke
    Ishikawa, Yozo
    Hattanda, Fumihiko
    Kusunoki, Yoshihiro
    Matsuoka, Naoko
    Yamamoto, Junya
    Nakagaki, Tasuku
    Takeda, Hiroshi
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 93 - 93
  • [29] Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Anderegg, Manuel A.
    Dhayat, Nasser A.
    Sommer, Grit
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Fuster, Daniel G.
    KIDNEY MEDICINE, 2020, 2 (02) : 162 - 171
  • [30] Multicenter Real-Life Experience With Tolvaptan Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease
    Duriseti, Parikshit
    Wigerinck, Stijn
    Chedid, Maroun
    Radhakrishnan, Yeshwanter
    Mao, Michael A.
    Hommos, Musab S.
    Garg, Arvind K.
    Zoghby, Ziad
    Keddis, Mira T.
    Trautman, Christopher L.
    Dahlen, Erin
    Gay, Melissa K.
    Mcfadden, Jennifer E.
    Bhat, Samrat V.
    Harris, Peter C.
    Erickson, Stephen B.
    Hogan, Marie C.
    Torres, Vicente E.
    Chebib, Fouad T.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 161 - 161
12345